{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:12:49Z","timestamp":1781853169152,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is an urgent need to develop vaccines against pathogenic bacteria. However, this is often hindered by antigenic diversity and difficulties encountered manufacturing membrane proteins. Here we show how to use structure-based design to develop chimeric antigens (ChAs) for subunit vaccines. ChAs are generated against serogroup B\n                    <jats:italic>Neisseria meningitidis<\/jats:italic>\n                    (MenB), the predominant cause of meningococcal disease in wealthy countries. MenB ChAs exploit factor H binding protein (fHbp) as a molecular scaffold to display the immunogenic VR2 epitope from the integral membrane protein PorA. Structural analyses demonstrate fHbp is correctly folded and the PorA VR2 epitope adopts an immunogenic conformation. In mice, immunisation with ChAs generates fHbp and PorA antibodies that recognise the antigens expressed by clinical MenB isolates; these antibody responses correlate with protection against meningococcal disease. Application of ChAs is therefore a potentially powerful approach to develop multivalent subunit vaccines, which can be tailored to circumvent pathogen diversity.\n                  <\/jats:p>","DOI":"10.1038\/s41467-018-03146-7","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T06:12:40Z","timestamp":1520403160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Structure-based design of chimeric antigens for multivalent protein vaccines"],"prefix":"10.1038","volume":"9","author":[{"given":"S.","family":"Hollingshead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Jongerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Exley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9287-8053","authenticated-orcid":false,"given":"S. M.","family":"Lea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"3146_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1201-9712(03)90011-7","volume":"7","author":"J Ar\u00edstegui","year":"2003","unstructured":"Ar\u00edstegui, J. et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J. Infect. Dis. 7, 143\u2013151 (2003).","journal-title":"Int J. Infect. Dis."},{"key":"3146_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1128\/CVI.00089-15","volume":"22","author":"TF Murphy","year":"2015","unstructured":"Murphy, T. F. Vaccines for nontypeable Haemophilus influenzae: the future is now. Clin. Vaccine Immunol. 22, 459\u2013466 (2015).","journal-title":"Clin. Vaccine Immunol."},{"key":"3146_CR3","doi-asserted-by":"publisher","first-page":"e01792","DOI":"10.1128\/mBio.01792-15","volume":"7","author":"LE Keller","year":"2016","unstructured":"Keller, L. E., Robinson, D. A. & McDaniel, L. S. Nonencapsulated Streptococcus pneumoniae: emergence and pathogenesis. MBio 7, e01792 (2016).","journal-title":"MBio"},{"key":"3146_CR4","doi-asserted-by":"publisher","first-page":"20120147","DOI":"10.1098\/rstb.2012.0147","volume":"368","author":"MC Maiden","year":"2013","unstructured":"Maiden, M. C. The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20120147 (2013).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"3146_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/pmic.200500086","volume":"6","author":"A Schaller","year":"2006","unstructured":"Schaller, A. et al. Rapid typing of Moraxella catarrhalis subpopulations based on outer membrane proteins using mass spectrometry. Proteomics 6, 172\u2013180 (2006).","journal-title":"Proteomics"},{"key":"3146_CR6","unstructured":"Surveillance of antimicrobial resistance in Neisseria gonorrhoeae Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/567602\/GRASP_Report_2016.pdf(Public Health England, 2016)."},{"key":"3146_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","volume":"2","author":"J Finne","year":"1983","unstructured":"Finne, J., Leinonen, M. & Makela, P. H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2, 355\u2013357 (1983).","journal-title":"Lancet"},{"key":"3146_CR8","unstructured":"Antimicrobial Resistance: Global Report on Surveillance 2014 (World Health Organisation, 2014)."},{"key":"3146_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.chom.2008.05.004","volume":"3","author":"JL Telford","year":"2008","unstructured":"Telford, J. L. Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 3, 408\u2013416 (2008).","journal-title":"Cell Host Microbe"},{"key":"3146_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.sbi.2008.07.001","volume":"18","author":"EP Carpenter","year":"2008","unstructured":"Carpenter, E. P., Beis, K., Cameron, A. D. & Iwata, S. Overcoming the challenges of membrane protein crystallography. Curr. Opin. Struct. Biol. 18, 581\u2013586 (2008).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"3146_CR11","first-page":"195","volume":"14","author":"GV Sierra","year":"1991","unstructured":"Sierra, G. V. et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14, 195\u2013210 (1991).","journal-title":"NIPH Ann."},{"key":"3146_CR12","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1097\/01.inf.0000147645.53942.00","volume":"23","author":"J O\u2019Hallahan","year":"2004","unstructured":"O\u2019Hallahan, J., Lennon, D. & Oster, P. The strategy to control New Zealand\u2019s epidemic of group B meningococcal disease. Pediatr. Infect. Dis. J. 23, S293\u2013S298 (2004).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"3146_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","author":"G Bjune","year":"1991","unstructured":"Bjune, G. et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093\u20131096 (1991).","journal-title":"Lancet"},{"key":"3146_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0264-410X(89)90194-1","volume":"7","author":"K Saukkonen","year":"1989","unstructured":"Saukkonen, K., Leinonen, M., Abdillahi, H. & Poolman, J. T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7, 325\u2013328 (1989).","journal-title":"Vaccine"},{"key":"3146_CR15","unstructured":"Blake, M. & Gotschilch, E. in Bacterial Outer Membranes as Model Systems (ed. Inouye, M.) 377\u2013400 (John Wiley and Sons, New York, 1987)."},{"key":"3146_CR16","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1128\/iai.59.9.2963-2971.1991","volume":"59","author":"P van der Ley","year":"1991","unstructured":"van der Ley, P., Heckels, J. E., Virji, M., Hoogerhout, P. & Poolman, J. T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59, 2963\u20132971 (1991).","journal-title":"Infect. Immun."},{"key":"3146_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","volume":"13","author":"DR Martin","year":"2006","unstructured":"Martin, D. R., Ruijne, N., McCallum, L., O\u2019Hallahan, J. & Oster, P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13, 486\u2013491 (2006).","journal-title":"Clin. Vaccine Immunol."},{"key":"3146_CR18","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","volume":"27","author":"J Holst","year":"2009","unstructured":"Holst, J. et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27, B3\u2013B12 (2009).","journal-title":"Vaccine"},{"key":"3146_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","volume":"14","author":"I Claassen","year":"1996","unstructured":"Claassen, I. et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14, 1001\u20131008 (1996).","journal-title":"Vaccine"},{"key":"3146_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","volume":"13","author":"P van der Ley","year":"1995","unstructured":"van der Ley, P., van der Biezen, J. & Poolman, J. T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13, 401\u2013407 (1995).","journal-title":"Vaccine"},{"key":"3146_CR21","unstructured":"van den Dobbelsteen, G. et al.\u00a0From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine. In International Pathogenic Neisseria Conference, 153 (Milwaukee, WI, 2004)."},{"key":"3146_CR22","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1128\/IAI.71.11.6367-6371.2003","volume":"71","author":"TA Luijkx","year":"2003","unstructured":"Luijkx, T. A. et al. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect. Immun. 71, 6367\u20136371 (2003).","journal-title":"Infect. Immun."},{"key":"3146_CR23","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/nbt1261","volume":"24","author":"JB Ulmer","year":"2006","unstructured":"Ulmer, J. B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24, 1377\u20131383 (2006).","journal-title":"Nat. Biotechnol."},{"key":"3146_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","volume":"177","author":"G Madico","year":"2006","unstructured":"Madico, G. et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177, 501\u2013510 (2006).","journal-title":"J. Immunol."},{"key":"3146_CR25","doi-asserted-by":"publisher","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","volume":"176","author":"MC Schneider","year":"2006","unstructured":"Schneider, M. C. et al. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176, 7566\u20137575 (2006).","journal-title":"J. Immunol."},{"key":"3146_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature07769","volume":"458","author":"MC Schneider","year":"2009","unstructured":"Schneider, M. C. et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458, 890\u2013893 (2009).","journal-title":"Nature"},{"key":"3146_CR27","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","author":"M Pizza","year":"2000","unstructured":"Pizza, M. et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816\u20131820 (2000).","journal-title":"Science"},{"key":"3146_CR28","unstructured":"Jolley, K. A. & Maiden, M. C. Neisseria Multi Locus Sequence Typing website.\n                           http:\/\/pubmlst.org\/neisseria\/ (Oxford University, 2005)."},{"key":"3146_CR29","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1099\/mic.0.027995-0","volume":"155","author":"C Brehony","year":"2009","unstructured":"Brehony, C., Wilson, D. J. & Maiden, M. C. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155, 4155\u20134169 (2009).","journal-title":"Microbiology"},{"key":"3146_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1086\/600141","volume":"200","author":"E Murphy","year":"2009","unstructured":"Murphy, E. et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200, 379\u2013389 (2009).","journal-title":"J. Infect. Dis."},{"key":"3146_CR31","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","volume":"72","author":"LD Fletcher","year":"2004","unstructured":"Fletcher, L. D. et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72, 2088\u20132100 (2004).","journal-title":"Infect. Immun."},{"key":"3146_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1084\/jem.20021911","volume":"197","author":"V Masignani","year":"2003","unstructured":"Masignani, V. et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med 197, 789\u2013799 (2003).","journal-title":"J. Exp. Med"},{"key":"3146_CR33","doi-asserted-by":"publisher","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","volume":"30","author":"D Serruto","year":"2012","unstructured":"Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M. & Rappuoli, R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30, B87\u2013B97 (2012).","journal-title":"Vaccine"},{"key":"3146_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/978-1-4939-3387-7_25","volume":"1403","author":"LR Green","year":"2016","unstructured":"Green, L. R. et al. Approach to the discovery, development, and evaluation of a novel Neisseria meningitidis serogroup B vaccine. Methods Mol. Biol. 1403, 445\u2013469 (2016).","journal-title":"Methods Mol. Biol."},{"key":"3146_CR35","first-page":"780","volume":"10","author":"N Andrews","year":"2003","unstructured":"Andrews, N., Borrow, R. & Miller, E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab Immunol. 10, 780\u2013786 (2003).","journal-title":"Clin. Diagn. Lab Immunol."},{"key":"3146_CR36","doi-asserted-by":"publisher","first-page":"S537","DOI":"10.1093\/clinids\/9.Supplement_5.S537","volume":"9","author":"MM Frank","year":"1987","unstructured":"Frank, M. M., Joiner, K. & Hammer, C. The function of antibody and complement in the lysis of bacteria. Rev. Infect. Dis. 9, S537\u2013S545 (1987).","journal-title":"Rev. Infect. Dis."},{"key":"3146_CR37","doi-asserted-by":"crossref","first-page":"9357","DOI":"10.1016\/S0021-9258(17)39372-9","volume":"260","author":"PH Poon","year":"1985","unstructured":"Poon, P. H., Phillips, M. L. & Schumaker, V. N. Immunoglobulin M possesses two binding sites for complement subcomponent C1q, and soluble 1:1 and 2:1 complexes are formed in solution at reduced ionic strength. J. Biol. Chem. 260, 9357\u20139365 (1985).","journal-title":"J. Biol. Chem."},{"key":"3146_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0161-5890(79)90010-5","volume":"16","author":"NC Hughes-Jones","year":"1979","unstructured":"Hughes-Jones, N. C. & Gardner, B. Reaction between the isolated globular sub-units of the complement component C1q and IgG-complexes. Mol. Immunol. 16, 697\u2013701 (1979).","journal-title":"Mol. Immunol."},{"key":"3146_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/(SICI)1097-0134(199709)29:1<113::AID-PROT9>3.0.CO;2-G","volume":"29","author":"JM van den Elsen","year":"1997","unstructured":"van den Elsen, J. M. et al. Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: crystal structure of a Fab fragment in complex with a fluorescein-conjugated peptide. Proteins 29, 113\u2013125 (1997).","journal-title":"Proteins"},{"key":"3146_CR40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0022-2836(03)00377-2","volume":"328","author":"CJ Oomen","year":"2003","unstructured":"Oomen, C. J. et al. Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations. J. Mol. Biol. 328, 1083\u20131089 (2003).","journal-title":"J. Mol. Biol."},{"key":"3146_CR41","unstructured":"Meningitis Research Foundation Meningococcus Genome Library. https:\/\/pubmlst.org\/bigsdb?db=pubmlst_neisseria_mrfgenomes (2011)."},{"key":"3146_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jm3011433","volume":"56","author":"SK Bagal","year":"2013","unstructured":"Bagal, S. K. et al. Ion channels as therapeutic targets: a drug discovery perspective. J. Med. Chem. 56, 593\u2013624 (2013).","journal-title":"J. Med. Chem."},{"key":"3146_CR43","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1128\/IAI.73.11.7558-7568.2005","volume":"73","author":"W Zhu","year":"2005","unstructured":"Zhu, W. et al. Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles. Infect. Immun. 73, 7558\u20137568 (2005).","journal-title":"Infect. Immun."},{"key":"3146_CR44","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1099\/00221287-139-8-1729","volume":"139","author":"M Christodoulides","year":"1993","unstructured":"Christodoulides, M., McGuinness, B. T. & Heckels, J. E. Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide. J. Gen. Microbiol. 139, 1729\u20131738 (1993).","journal-title":"J. Gen. Microbiol."},{"key":"3146_CR45","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jmb.2005.06.061","volume":"351","author":"CJ Oomen","year":"2005","unstructured":"Oomen, C. J. et al. Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J. Mol. Biol. 351, 1070\u20131080 (2005).","journal-title":"J. Mol. Biol."},{"key":"3146_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0264-410X(99)00190-5","volume":"18","author":"M Christodoulides","year":"1999","unstructured":"Christodoulides, M., Rattue, E. & Heckels, J. E. Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin. Vaccine 18, 131\u2013139 (1999).","journal-title":"Vaccine"},{"key":"3146_CR47","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1128\/iai.63.9.3473-3478.1995","volume":"63","author":"P Hoogerhout","year":"1995","unstructured":"Hoogerhout, P. et al. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect. Immun. 63, 3473\u20133478 (1995).","journal-title":"Infect. Immun."},{"key":"3146_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/psc.2482","volume":"19","author":"JA Robinson","year":"2013","unstructured":"Robinson, J. A. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. J. Pept. Sci. 19, 127\u2013140 (2013).","journal-title":"J. Pept. Sci."},{"key":"3146_CR49","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82, 488\u2013496 (2004).","journal-title":"Immunol. Cell Biol."},{"key":"3146_CR50","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1128\/iai.56.12.3064-3066.1988","volume":"56","author":"PJ Baker","year":"1988","unstructured":"Baker, P. J. et al. Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect. Immun. 56, 3064\u20133066 (1988).","journal-title":"Infect. Immun."},{"key":"3146_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.0300-9475.2004.01362.x","volume":"59","author":"TE Michaelsen","year":"2004","unstructured":"Michaelsen, T. E., Kolberg, J., Aase, A., Herstad, T. K. & H\u00f8iby, E. A. The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis. Scand. J. Immunol. 59, 34\u201339 (2004).","journal-title":"Scand. J. Immunol."},{"key":"3146_CR52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1209368","volume":"334","author":"ML Azoitei","year":"2011","unstructured":"Azoitei, M. L. et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 373\u2013376 (2011).","journal-title":"Science"},{"key":"3146_CR53","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.str.2010.06.010","volume":"18","author":"BE Correia","year":"2010","unstructured":"Correia, B. E. et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116\u20131126 (2010).","journal-title":"Structure"},{"key":"3146_CR54","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jmb.2011.04.044","volume":"409","author":"JS McLellan","year":"2011","unstructured":"McLellan, J. S. et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409, 853\u2013866 (2011).","journal-title":"J. Mol. Biol."},{"key":"3146_CR55","doi-asserted-by":"publisher","first-page":"17880","DOI":"10.1073\/pnas.1004728107","volume":"107","author":"G Ofek","year":"2010","unstructured":"Ofek, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA 107, 17880\u201317887 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3146_CR56","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1021\/jm00117a022","volume":"31","author":"JD Aebi","year":"1988","unstructured":"Aebi, J. D., Guillaume, D., Dunlap, B. E. & Rich, D. H. Synthesis, conformation, and immunosuppressive activity of a conformationally restricted cyclosporine lactam analogue. J. Med Chem. 31, 1805\u20131815 (1988).","journal-title":"J. Med Chem."},{"key":"3146_CR57","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1021\/jo00340a023","volume":"47","author":"RM Freidinger","year":"1982","unstructured":"Freidinger, R. M., Perlow, D. S. & Veber, D. F. Protected lactam-bridged dipeptides for use as conformational constraints in peptides. J. Org. Chem. 47, 104\u2013109 (1982).","journal-title":"J. Org. Chem."},{"key":"3146_CR58","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1093\/nar\/25.16.3371","volume":"25","author":"SH Ke","year":"1997","unstructured":"Ke, S. H. & Madison, E. L. Rapid and efficient site-directed mutagenesis by single-tube \u2018megaprimer\u2019 PCR method. Nucleic Acids Res. 25, 3371\u20133372 (1997).","journal-title":"Nucleic Acids Res"},{"key":"3146_CR59","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1084\/jem.20041548","volume":"201","author":"RM Exley","year":"2005","unstructured":"Exley, R. M. et al. Available carbon source influences the resistance of Neisseria meningitidis against complement. J. Exp. Med. 201, 1637\u20131645 (2005).","journal-title":"J. Exp. Med."},{"key":"3146_CR60","doi-asserted-by":"publisher","first-page":"e1003528","DOI":"10.1371\/journal.ppat.1003528","volume":"9","author":"I Jongerius","year":"2013","unstructured":"Jongerius, I. et al. Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor h binding protein. PLoS Pathog. 9, e1003528 (2013).","journal-title":"PLoS Pathog."},{"key":"3146_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol. Crystallogr. 67, 235\u2013242 (2011).","journal-title":"Acta Crystallogr D Biol. Crystallogr"},{"key":"3146_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240\u2013255 (1997).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"3146_CR63","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D. Biol Crystallogr."},{"key":"3146_CR64","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1107\/S0021889809023528","volume":"42","author":"PV Afonine","year":"2009","unstructured":"Afonine, P. V., Grosse-Kunstleve, R. W., Urzhumtsev, A. & Adams, P. D. Automatic multiple-zone rigid-body refinement with a large convergence radius. J. Appl. Crystallogr. 42, 607\u2013615 (2009).","journal-title":"J. Appl. Crystallogr."},{"key":"3146_CR65","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"3146_CR66","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1107\/S0907444913000462","volume":"69","author":"PV Afonine","year":"2013","unstructured":"Afonine, P. V., Grosse-Kunstleve, R. W., Adams, P. D. & Urzhumtsev, A. Bulk-solvent and overall scaling revisited: faster calculations, improved results. Acta Crystallogr. D Biol. Crystallogr. 69, 625\u2013634 (2013).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"3146_CR67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1107\/S0907444911047834","volume":"68","author":"JJ Headd","year":"2012","unstructured":"Headd, J. J. et al. Use of knowledge-based restraints in phenix.refine to improve macromolecular refinement at low resolution. Acta Crystallogr. D Biol. Crystallogr. 68, 381\u2013390 (2012).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"3146_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03146-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T08:21:55Z","timestamp":1671524515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03146-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["3146"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-03146-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/187336","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]},"assertion":[{"value":"21 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have filed a patent on Chimeric antigens (ref GB1614687, PCT filing date: 31st August 2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1051"}}